Overall Survival and Progressive Free Survival in patient with infantile Osteopetrosis who receive allogeneic HSCT 1 year [clinicaltrials_resource:d5135b548250eb7cd109bd047c4ec1b5]

Overall Survival and Progressive Free Survival in patient with infantile Osteopetrosis who receive allogeneic HSCT 1 year [clinicaltrials_resource:d5135b548250eb7cd109bd047c4ec1b5]

For sibling full match: Busulfan 16 mg/kg >5year - 20 mg/kg <5year po Cyclophosphamide 200 mg/kg iv For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood: Busulfan 16 mg/kg >5year - 20 mg/kg <5year po Cyclophosphamide 200 mg/kg iv ATG rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg For haploidentical: Busulfan 16 mg/kg >5year - 20 mg/kg <5year po Cyclophosphamide 200 mg/kg iv Fludarabine 160 mg/m^2
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:d5135b548250eb7cd109bd047c4ec1b5
Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis [clinicaltrials:NCT01087398]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Overall Survival and Progressive Free Survival in patient with infantile Osteopetrosis who receive allogeneic HSCT 1 year [clinicaltrials_resource:d5135b548250eb7cd109bd047c4ec1b5]

For sibling full match: Busulfan 16 mg/kg >5year - 20 mg/kg <5year po Cyclophosphamide 200 mg/kg iv For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood: Busulfan 16 mg/kg >5year - 20 mg/kg <5year po Cyclophosphamide 200 mg/kg iv ATG rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg For haploidentical: Busulfan 16 mg/kg >5year - 20 mg/kg <5year po Cyclophosphamide 200 mg/kg iv Fludarabine 160 mg/m^2
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:d5135b548250eb7cd109bd047c4ec1b5
Bio2RDF identifier
d5135b548250eb7cd109bd047c4ec1b5
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:d5135b548250eb7cd109bd047c4ec1b5
measure [clinicaltrials_vocabulary:measure]
Overall Survival and Progressi ...... is who receive allogeneic HSCT
time frame [clinicaltrials_vocabulary:time-frame]
description
For sibling full match: Busulf ...... g/kg iv Fludarabine 160 mg/m^2
identifier
clinicaltrials_resource:d5135b548250eb7cd109bd047c4ec1b5
title
Overall Survival and Progressi ...... receive allogeneic HSCT 1 year
@en
inDataset
type
label
Overall Survival and Progressi ...... 35b548250eb7cd109bd047c4ec1b5]
@en